Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

OBJECTIVES: To estimate the real-world effectiveness of sotrovimab against severe, critical, or fatal COVID-19 in Qatar at a time in which most SARS-CoV-2 incidences occurred due to the BA.2 Omicron subvariant. METHODS: We conducted a matched case-control study among all individuals eligible for sot...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaqout, Ahmed, Almaslamani, Muna A., Chemaitelly, Hiam, Hashim, Samar A., Ittaman, Ajithkumar, Alimam, Abeir, Rustom, Fatma, Daghfal, Joanne, Abukhattab, Mohammed, AlMukdad, Sawsan, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Butt, Adeel A., Bertollini, Roberto, Al-Khal, Abdullatif, Omrani, Ali S., Abu-Raddad, Laith J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484101/
https://www.ncbi.nlm.nih.gov/pubmed/36218031
http://dx.doi.org/10.1016/j.ijid.2022.09.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484101/
https://www.ncbi.nlm.nih.gov/pubmed/36218031
http://dx.doi.org/10.1016/j.ijid.2022.09.023

Ejemplares similares